Broncus Completes $Tens of Millions Series D Financing to Accelerate Integrated Precision Interventional Solutions for Lung Diseases

Broncus, a global leader in precision interventional diagnosis and treatment of lung diseases, recently announced the completion of its tens-of-millions-of-US-dollars Series D financing round. The round was led by FountainVest Partners, with participation from Exome Asset Management, Summer Capital, Valliance Capital, and other investors.

Kunbo Medical is a company focused on the research, development, and production of precise interventional diagnostic and therapeutic technologies for pulmonary diseases. Leveraging the world’s only real-time image fusion-based whole-lung navigation technology, Kunbo Medical has established a robust patent moat and built an integrated pipeline of AI- and algorithm-driven pulmonary diagnostic and therapeutic products spanning from diagnosis to treatment.

Following this round of financing, Kunbo Medical will continue to invest in the research and development, clinical studies, and global market expansion of its core products, including interventional therapies for lung cancer and emphysema. The company aims to accelerate the realization of a closed-loop, integrated solution spanning from interventional diagnosis to treatment under whole-lung navigation. Previously, Kunbo Medical completed three rounds of financing, with investors including renowned global venture capital firms and industry leaders such as Qiming Venture Partners, ClearPool Capital, Baidu Capital, Jishi Capital, DH Capital, and Intuitive Surgical.

“Amid the ravaging COVID-19 pandemic, global attention to lung health has reached an unprecedented level. Kunbo Medical’s whole-lung navigation platform represents a critical technological breakthrough for minimally invasive interventional diagnosis and treatment of pulmonary diseases,” said Zhan Guowei, CEO of Kunbo Medical. “Leveraging the world’s only real-time image fusion-based whole-lung navigation technology, Kunbo Medical provides novel, precise interventional therapeutic solutions for two major pulmonary malignancies—lung cancer and emphysema—as well as a broader range of lung diseases.”

Li Zhen, Managing Director of FountainVest Partners, stated, “FountainVest Partners is committed to collaborating with industry leaders that possess innovative capabilities. Kunbo Medical is one of the pioneers in the field of precise interventional diagnosis and treatment for lung diseases, having achieved full coverage of its product portfolio from diagnosis to therapy. We look forward to leveraging FountainVest’s domestic and international medical resources and expertise to strongly support Kunbo Medical’s development as it reaches new heights.”

Kunbo Medical has secured nearly 200 patents worldwide. Its globally unique transbronchial out-of-airway navigation technology has enabled Bronchoscopic Transparenchymal Nodule Access (BTPNA), meeting the clinical demand for high-accuracy access to the entire lung, addressing the low diagnostic rates and therapeutic limitations of existing methods, and ushering in a new era of precise localization and treatment for lesions outside the pulmonary airways. Following the successful completion of multiple financing rounds, Kunbo Medical has rapidly advanced the independent R&D and global commercialization layout of its therapeutic product pipeline. The successive market launch of these products will facilitate the medical community in delivering precise interventional treatments for lung cancer and emphysema, two major diseases, thereby revolutionizing the standards of care for pulmonary diseases.

Kunbo Medical, a global leader in precise interventional diagnosis and treatment of pulmonary diseases, provides the world’s only real-time image-fusion, whole-lung navigation-integrated precision solution for diagnosis and therapy. The company has established R&D and manufacturing bases in China and the United States, with all technologies independently developed. It has over 450 patents granted or applied for in major global markets, including China, the United States, and Europe. Leveraging its core patented products, the company pioneered the Bronchoscopic Transparenchymal Nodule Access (BTPNA) procedure, meeting clinical demands for high-accuracy access to lesions throughout the entire lung. Kunbo Medical’s LungPro Whole-Lung Diagnostic and Therapeutic Navigation System and LungPoint Augmented Reality Navigation System have all received regulatory approval for commercial sale in China, the United States, Europe, and other regions. Its integrated diagnostic and therapeutic consumables, built upon its navigation technology platform, are at the forefront of global innovation.

FountainVest Partners is a leading market-oriented, independently operated private equity investment firm in Asia. FountainVest focuses on long-term investments in industry-leading companies and works closely with management teams to provide support in strategy, operations, finance, and capital markets, thereby driving corporate growth and creating exceptional value. The firm has completed a series of successful landmark investments across Asia, Europe, and the United States, with key focus areas including consumer, media and technology, healthcare, industrials, and financial services.

Exome Asset Management, based in New York, was founded by Mr. Samuel D. Isaly and focuses on investments in the global biopharmaceutical sector. As one of the founding and managing partners of OrbiMed Advisors LLC, a globally renowned biomedical fund, he led OrbiMed to grow its assets under management from $1 billion in 1998 to $15 billion in 2018. Mr. Samuel D. Isaly currently serves as Chairman Emeritus of OrbiMed.

CHIYUAN CAPITAL is a multi-strategy investment firm that brings together seasoned financial professionals from the industry. It focuses on global investment opportunities, with an emphasis on precise investments and strategic positioning in the healthcare, consumer, education, logistics, and fintech sectors. As a multi-strategy investor with a global perspective, CHIYUAN CAPITAL employs a top-down research approach to identify companies undergoing transformation—particularly those where CHIYUAN CAPITAL can facilitate value realization and which may become targets for strategic investment or mergers and acquisitions by Chinese institutions.

Pulin Capital is a fund focused on long-term and value investing, adopting a bottom-up investment approach, and has successfully invested in several high-quality enterprises. Mr. Li Lin is the founder and Chief Investment Officer of the fund, with over 20 years of investment experience, and was recently appointed as a member of the Listing Committee of the Stock Exchange of Hong Kong Limited. Mr. Li Lin previously managed Asia-Pacific equity investments at renowned international funds CQS and Aubrey Capital Management, possessing profound understanding and insight into the Greater China market.